MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$10,413,205
EPS
-$0.33
Unit: Dollar

Income Statement
2025-12-31
General and administrative expenses
8,103,280
Research and development expenses
2,435,569
Total operating costs
10,538,849
Interest income
125,644
Net loss
-10,413,205
Basic EPS
-0.33
Diluted EPS
-0.33
Basic Average Shares
31,653,094
Diluted Average Shares
31,653,094
Unit: Dollar.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$10,413,205 Interest income$125,644 Total operating costs$10,538,849 General andadministrative expenses$8,103,280 Research and developmentexpenses$2,435,569

Telomir Pharmaceuticals, Inc. (TELO)

Telomir Pharmaceuticals, Inc. (TELO)